Dr. Reddy’s launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
Proud to announce the launch of Toripalimab in India, the first and only immuno-oncology drug approved by various regulatory authorities around the world such as the USFDA, DCGI, EMA, MHRA and others for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). Toripalimab is a New Biological Entity (NBE). The combination of Toripalimab … Read more